Please login to the form below

Not currently logged in
Email:
Password:

Novartis receives Rasilez approval in China

Novartis has received regulatory approval for its high blood pressure treatment Rasilez in China

Novartis has received regulatory approval for its high blood pressure treatment Rasilez (aliskiren) in China. The first-in-class direct renin inhibitor is approved for use as a treatment on its own, as well as in combination with other high blood pressure medication.

Rasilez is already approved in 80 countries and is known as Tekturna in the US.  It works by directly inhibiting the activity of renin, an enzyme produced by the kidneys that can cause blood vessels to narrow. This can then lead to high blood pressure.

"We are pleased that our continued investment in China enables us to bring treatment options to patients that address the needs of this growing market," said David Epstein, division head of Novartis Pharmaceuticals. "By adapting our development timelines for Rasilez we have been able to provide patients in China with timely access to this novel therapy for high blood pressure."

According to Novartis, high blood pressure is the "leading preventable cause of death in China" with two million deaths attributed to the condition occurring there each year. Around 153 million adults in the country are thought to be affected by the condition currently, with 76 per cent of patients not being treated to an optimum level, according to 'Premature Deaths Attributable to Blood Pressure in China: A Prospective Cohort Study', published in The Lancet.

Speaking on the approval, Dr Yong Huo, president-elect of the Chinese Society of Cardiology, Department of Cardiology, Peking University First Hospital, said: “Modifications in lifestyle and diet have led to high blood pressure becoming a significant and growing problem in China.

"Because the disease has no apparent symptoms, awareness as well as treatment and control of the condition are very low. As a result, there is a clear need for innovative high blood pressure treatments in China to enable more patients to successfully manage their condition."

20th July 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics